Panitumumab. en las nuevas guías de CCRm - page 44

There is no unequivocal evidence to administer

the alternative EGFR antibody, if a patient is

refractory to one of the EGFR antibodies [I, C].

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,34,35,36,37,38,39,40,41,42,43 45,46,47